Product Description: Imsidolimab (ANB 019) is a high-affinity, humanized monoclonal antibody of anti-IL-36R. Imsidolimab antagonizes IL-36 cytokine signal transduction. Imsidolimab has potential application in generalized pustular psoriasis (GPP) and other inflammatory skin diseases[1][2].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Gudjonsson J E, et al. 34617 Imsidolimab in the treatment of adult subjects with generalized pustular psoriasis: Design of a pivotal phase 3 clinical trial and a long-term extension study[J]. Journal of the American Academy of Dermatology, 2022, 87(3): AB70./[2]Iznardo H, et al. Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease. Int J Mol Sci. 2021 Apr 21;22(9):4344.
CAS Number: 2102543-86-0
Molecular Weight: N/A
Research Area: Inflammation/Immunology
Solubility: 10 mM in DMSO
Target: Interleukin Related
English
Deutsch
